Management of cetuximab-induced skin toxicity with the prophylactic use of topical vitamin K1 cream

Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-33.10.1093/annonc/mdi27916012181Search in Google Scholar

van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.10.1056/NEJMoa080501919339720Search in Google Scholar

Ocvirk J. Advances in the treatment of metastatic colorectal carcinoma. Radiol Oncol 2009; 43: 1-8.10.2478/v10019-009-0004-1Search in Google Scholar

Lacouture ME. Insights into the pathophysiology and management of dermatologic toxicities to EGFR-targeted therapies in colorectal cancer. Cancer Nurs 2007; 30: S17-26.10.1097/01.NCC.0000281758.85704.9b17666987Search in Google Scholar

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.10.1093/jnci/92.3.20510655437Search in Google Scholar

Erbitux. Summary of product characteristics. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/erbitux/H-558-PI-en.pdfSearch in Google Scholar

Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 cream. Radiol Oncol 2008; 42: 215-24.10.2478/v10019-008-0022-4Search in Google Scholar

The international response to Helsinki VI - The WMA's Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, as adopted by the 52nd WMA General Assembly. Edinburgh; October 2000. Available at http://www.wma.net/en/20activities/10ethics/10helsinki/index.htmlSearch in Google Scholar

Tan EH, Chan A. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. Ann Pharmacother 2009; 43: 1658-66.10.1345/aph.1M24119755624Search in Google Scholar

Li TH, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Targ Oncol 2009; 4: 107-19.10.1007/s11523-009-0114-019452131Search in Google Scholar

Ocvirk J, Rebersek M. Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. [Abstract]. J Clin Oncol 2009; 27(Suppl): e15087.10.1200/jco.2009.27.15_suppl.e15087Search in Google Scholar